Read transcripts of debates in both Houses
Produced by Commons Library, Lords Library and Parliamentary Office Science and Technology
Search for Members by name, postcode, constituency and party
Learn about their experience, knowledge and interests
Celebrating people who have made Parliament a positive, inclusive working environment
Four staff networks for people to discuss and consider issues.
Contact your MP or a Member of the House of Lords about an issue that matters to you
Sign up for the Your Parliament newsletter to find out how you can get involved
Take a tour of Parliament and enjoy a delicious afternoon tea by the River Thames
See some of the sights you’ll encounter on a tour of Parliament
Book a school visit, classroom workshop or teacher-training session
Access videos, worksheets, lesson plans and games
Follow this EDM by:
That this House is deeply concerned about the effects of the anti-depressant drug Seroxat; notes that the World Health Organisation puts the drug at the top of its league table of drugs that have difficulties of withdrawal and that over 1,000 Seroxat users in the United Kingdom are taking legal action against the manufacturer, Glaxo SmithKline, after funding that the drug can lead to dependency and result in severe withdrawal symptoms including muscle spasms, insomnia, anxiety and depression and, in some cases, aggression and violence; is further concerned that the labelling of the drug does not mention the difficulties of withdrawal and that such symptoms are often misdiagnosed by doctors as a relapse into depression; further notes that the manufacturer has already been forced to drop adverts for the drug in the United States of America after a court rules that they could be misleading; and calls upon the Department of Health to look into the labelling and availability of the drug.
Total number of signatures: 100
Showing 100 out of 100